Capricor - Rasio nilai perusahaan marang dodolan CAPR

The Capricor Therapeutics team brings together leading cell biologists motivated by the fight against cardiological pathologies. Anticipation of the BLA filing for Duchenne muscular dystrophy therapy serves as the primary driver, while production costs have already been priced in by the market. Strategic alliances with global players are accelerating expansion and M&A processes, which is confirmed by the EV-to-revenue multiple, where the latest value is recorded as 0.00.
CAPR (Capricor Therapeutics): rincian analitis lan laporan miturut indikator

Complex cryogenic logistics for biomaterials provide Capricor Therapeutics (CAPR) with high margins and operational resilience. This indicator compares the total enterprise value, excluding the impact of leverage, with the volume of generated revenue. It is critical for investors to evaluate this ratio to identify whether the asset is overbought or possesses growth potential. Analyzing the trend via the enterprise value-to-sales multiple allows market noise to be filtered out. Sharp deviations on the chart signal volatility risks or capital undervaluation.